
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly demonstrated a robust financial performance in the second quarter of 2025, surpassing expectations on both revenue and earnings while also raising its full-year guidance. Notably, Mounjaro's international sales surged by 60% quarter-over-quarter, fueled by successful market entries in Brazil, Mexico, and India, suggesting a strong growth trajectory for this product. Additionally, the anticipated launch of orforglipron, an oral GLP-1 option, is expected to enhance the company's competitive edge in the cardiometabolic market, further bolstering its revenue potential.
Bears say
Eli Lilly faces significant downside risks that contribute to a negative outlook on its stock, including potential pricing pressures and a disappointing trajectory for its key product, tirzepatide (Mounjaro). The company has also reported reduced prescription volumes for Zepbound, which is anticipated to hinder volumetric growth in the upcoming quarter. Furthermore, increasing competition from products like orforglipron, which poses a substantial threat to established offerings such as Ozempic, exacerbates these concerns regarding future revenue generation.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares